Piper Jaffray Companies restated their buy rating on shares of AbbVie Inc. (NYSE:ABBV) in a research report sent to investors on Friday morning. The firm currently has a $100.00 target price on the stock.

Several other equities analysts have also weighed in on ABBV. Jefferies Group LLC reiterated a buy rating on shares of AbbVie in a report on Friday, May 26th. Credit Suisse Group reiterated a hold rating and set a $65.00 price objective on shares of AbbVie in a report on Wednesday, June 7th. BidaskClub upgraded shares of AbbVie from a buy rating to a strong-buy rating in a report on Saturday, June 10th. Vetr lowered shares of AbbVie from a buy rating to a hold rating and set a $72.72 price objective on the stock. in a report on Wednesday, June 14th. Finally, Societe Generale upgraded shares of AbbVie from a hold rating to a buy rating in a report on Thursday, June 22nd. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. AbbVie currently has a consensus rating of Buy and a consensus target price of $82.38.

AbbVie (ABBV) traded down 2.07% during trading on Friday, reaching $87.37. The company’s stock had a trading volume of 20,441,496 shares. The stock’s 50-day moving average is $74.86 and its 200 day moving average is $69.44. AbbVie has a 12 month low of $55.06 and a 12 month high of $89.69. The company has a market cap of $139.28 billion, a P/E ratio of 21.49 and a beta of 1.48.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.02. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The firm had revenue of $6.94 billion for the quarter, compared to analyst estimates of $6.93 billion. During the same quarter in the prior year, the business earned $1.26 earnings per share. The business’s quarterly revenue was up 7.6% compared to the same quarter last year. On average, equities analysts forecast that AbbVie will post $5.52 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “AbbVie Inc. (ABBV) Given “Buy” Rating at Piper Jaffray Companies” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/16/abbvie-inc-abbv-given-buy-rating-at-piper-jaffray-companies.html.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be given a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a yield of 2.93%. The ex-dividend date is Thursday, October 12th. AbbVie’s payout ratio is 62.90%.

In other news, Director Edward J. Rapp acquired 4,000 shares of AbbVie stock in a transaction on Monday, July 31st. The stock was acquired at an average cost of $70.45 per share, with a total value of $281,800.00. Following the transaction, the director now owns 15,498 shares of the company’s stock, valued at approximately $1,091,834.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the company’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $85.02, for a total transaction of $705,666.00. Following the completion of the sale, the senior vice president now directly owns 93,099 shares of the company’s stock, valued at $7,915,276.98. The disclosure for this sale can be found here. Insiders sold a total of 373,191 shares of company stock valued at $26,598,305 over the last ninety days. 0.23% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the business. Investec Asset Management LTD grew its position in AbbVie by 3.6% in the 1st quarter. Investec Asset Management LTD now owns 166,978 shares of the company’s stock worth $10,880,000 after purchasing an additional 5,801 shares in the last quarter. Accident Compensation Corp grew its position in AbbVie by 24.7% in the 1st quarter. Accident Compensation Corp now owns 66,200 shares of the company’s stock worth $4,314,000 after purchasing an additional 13,100 shares in the last quarter. Clean Yield Group grew its position in AbbVie by 25.0% in the 1st quarter. Clean Yield Group now owns 9,598 shares of the company’s stock worth $625,000 after purchasing an additional 1,920 shares in the last quarter. Comerica Securities Inc. grew its position in AbbVie by 832.7% in the 1st quarter. Comerica Securities Inc. now owns 66,443 shares of the company’s stock worth $4,329,000 after purchasing an additional 59,319 shares in the last quarter. Finally, Suntrust Banks Inc. grew its position in AbbVie by 3.7% in the 1st quarter. Suntrust Banks Inc. now owns 1,216,484 shares of the company’s stock worth $79,265,000 after purchasing an additional 43,617 shares in the last quarter. 68.29% of the stock is owned by institutional investors and hedge funds.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.